|Articles|March 1, 2017
- Pharmaceutical Executive-03-01-2017
- Volume 37
- Issue 3
Pharmaceutical Executive, March 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 9 years ago
Big Data: Is It Crunch Time for Pharma?almost 9 years ago
Setting Sights on the Smart Supply Chainalmost 9 years ago
Global Pharma Deals with US Trade Overhaulsalmost 9 years ago
Precision Medicine and Big Dataalmost 9 years ago
Country Report: IrelandNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
3
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
4
FDA Sends Decision Letter to Vanda Pharmaceuticals for NDA of Hetlioz
5